-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 QU4Zts2vXYNWPIzQzHeiGBY+5LbPAAFiD4D8WpkmbHCZFHnH9XsXiHKELfTXL5Ko
 jgp3UhTyJrOdUTemLfwXfA==

<SEC-DOCUMENT>0000950123-10-069039.txt : 20100728
<SEC-HEADER>0000950123-10-069039.hdr.sgml : 20100728
<ACCEPTANCE-DATETIME>20100728160515
ACCESSION NUMBER:		0000950123-10-069039
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20100728
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100728
DATE AS OF CHANGE:		20100728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHAMPIONS BIOTECHNOLOGY, INC.
		CENTRAL INDEX KEY:			0000771856
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				521401755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17263
		FILM NUMBER:		10974433

	BUSINESS ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205
		BUSINESS PHONE:		410-369-0365

	MAIL ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS SPORTS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERNATIONAL GROUP INC
		DATE OF NAME CHANGE:	19860319
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c03901e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): July 28, 2010</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>CHAMPIONS BIOTECHNOLOGY, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>0-17263</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>52-1401755</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Science and Technology Park at Johns Hopkins<BR>855 N. Wolfe Street, Suite 619, Baltimore, MD<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>21205</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(410) 369-0365</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>Inapplicable<BR></B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>INFORMATION TO BE INCLUDED IN THE REPORT</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;2.02. Results of Operations and Financial Condition.</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&nbsp;28, 2010, Champions Biotechnology, Inc. (the &#147;<B>Company</B>&#148;) announced its results of
operations for its fiscal year ended April&nbsp;30, 2010. A copy of the Company&#146;s press release
announcing such results dated July&nbsp;28, 2010 is attached hereto as Exhibit&nbsp;99.1. This Form 8-K and
the attached exhibit are furnished to, but not filed with, the Securities and Exchange Commission
(&#147;<B>SEC</B>&#148;) and shall not be deemed to be incorporated by reference into any of the Company&#146;s filings
with the SEC under the Securities Act of 1933.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>(c)&nbsp;Exhibits</I>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The following exhibits are filed herewith:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;No.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release dated July&nbsp;28, 2010</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SIGNATURES</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><BR>
<B>CHAMPIONS BIOTECHNOLOGY, INC.</B><BR>
(Registrant)<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: July 28, 2010&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mark Schonau
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark Schonau&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c03901exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><U><B>Exhibit&nbsp;99.1</B></U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt">Champions Biotechnology, Inc.<BR>
NEWS<BR>
855 N. Wolfe Street, Suite&nbsp;619, Baltimore, Maryland 21205 USA.<BR>
Tel. 410-369-0365
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">For Immediate Release
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Champions Biotechnology Reports Fiscal 2010 Full-Year Financial Results</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Baltimore, MD, July&nbsp;28, 2010 </B>&#151; Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a
company engaged in the development of advanced preclinical platforms and tumor specific data to
enhance the value of oncology drugs, today announced its financial results for the fiscal year
ended April&nbsp;30, 2010. Full details of the Company&#146;s financial results will be available in the
Company&#146;s Form 10-K at www.championsbiotechnology.com.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">For the fiscal year ended April&nbsp;30, 2010, the Company&#146;s operating revenues were $4,893,000 as
compared to $3,710,000 for the fiscal year ended April&nbsp;30, 2009, an increase of 32%. The Company
generated $3,206,000 of revenue in fiscal 2010 from its Personalized Oncology services which
assists physicians by providing information that may enhance personalized treatment options for
their cancer patients and $1,687,000 of revenue from Preclinical eValuation services which assist
drug development companies in the evaluation of their oncology drug candidates.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Cost of Personalized Oncology services for fiscal 2010 totaled $1,181,000, which resulted in a
gross margin of 63% as compared to 50% in fiscal 2009. The overall increase in gross margin was
due to a greater mix of higher-margin business such as personalized vaccines programs during fiscal
2010.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Cost of Preclinical eValuation services for the year totaled $798,000, which resulted in a gross
margin of 53% compared to 34% in fiscal 2009. The higher margins in fiscal 2010 were a result from
increased efficiencies realized in the Company&#146;s second full year of operations.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Research and development expenses for fiscal 2010 totaled $2,695,000 as compared to $1,721,000 in
fiscal 2009. The increase in research and development expenses was mainly attributable to the
efforts in building the Company&#146;s own drug candidate pipeline and incurring license and option fees
for three of our drug compounds, patent fees related to the Company&#146;s SG-410 drug candidate and the
Biomerk Tumorgraft<SUP style="font-size: 85%; vertical-align: text-top">TM</SUP> expansion program which included the acquisition, propagation,
storage and characterization of tumors in Champions&#146; tumorgraft bank.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">General and administrative expenses for fiscal 2010 totaled $3,147,000 as compared to $2,127,000 in
fiscal 2009. The increase was principally due to the overall growth of the business, personnel and
operating expenses associated with staffing and outfitting the Company&#146;s Israel and United Kingdom
operations.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">For the fiscal year ended April&nbsp;30, 2010, the Company reported a net loss of $2,923,000 or ($0.09)
per share compared to a net loss of $2,242,000 or ($0.07) per share in fiscal 2009. In addition to
the factors described above, our net losses reflect non-cash expenses, i.e., share-based
compensation, patent expenses paid in common stock and depreciation of $800,000 or ($0.02) per
share in fiscal 2010 compared to $752,000 or ($0.02) in fiscal 2009.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The Company&#146;s cash position on April&nbsp;30, 2010 was $2,572,000 compared to $2,745,000 on April&nbsp;30,
2009 which included $1,017,000 held in a short term certificate of deposit.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Fiscal 2010 Highlights:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Experienced an increase in top-line revenues of 32% with overall gross margins
increasing from 49% to 60%, year-over-year;</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Achieved record results in the fourth quarter with revenues of $1,900,000;</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Experienced year-over-year top-line revenue growth of 290% in the Preclinical eValuation
business;</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Acquired three new drug compounds, now totaling four in development;</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Continued to expand its Biomerk Tumorgraft platform and has approximately 300
tumorgrafts available and/or in development at April&nbsp;30, 2010, representing all of the
major solid tumor indications;</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Launched its Live Tumor Banking program, which is detailed at our website:
www.personalizedcancertreatment.com;</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Entered into a collaboration agreement with PinnacleCare, which brings together two of
the leading companies in Personalized Medicine;</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Received signed subscription agreements totaling $3.0&nbsp;million of which $2.2&nbsp;million has
been received in its private placement to accredited investors; and</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Engaged Eric Rowinsky, M.D., a former Chief Medical Officer and Senior Vice President of
ImClone Systems, as a consultant to serve as the Company&#146;s first Chief Medical Officer.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">David Sidransky, M.D., Chairman of the Board of Champions Biotechnology, Inc., noted, &#147;The progress
made in 2010 has been very promising. As we move into 2011, the Company will continue to work in
developing drug compounds, and leveraging our tumorgraft platform.&#148; Dr.&nbsp;Sidransky noted that the
Company is now a global organization participating in opportunities for oncology care with
revenue-producing operations in the United States, United Kingdom and Israel.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">For more information regarding Champions Biotechnology&#146;s growing business and recent news,
please visit www.championsbiotechnology.com.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About Champions Biotechnology, Inc.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The
Company&#146;s Preclinical Platform is a novel approach based upon the implantation of primary human
tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk
Tumorgrafts&#153;) in a manner that preserves the biological characteristics of the original human
tumor. The Company believes that these Tumorgrafts closely reflect human cancer biology and their
response to drugs is more predictive of clinical outcomes in cancer patients.<BR>
Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to
develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress
through this early stage of development, the Company plans to sell, partner or license them to
pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its
predictive preclinical platform and tumor specific data to physicians for personalized patient care
and to Companies for evaluation of oncology drugs and drug candidates in models that integrate prognostic testing with biomarker discovery. Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating
development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.

</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>This press release contains &#147;forward-looking statements&#148; (within the meaning of the Private
Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions
Biotechnology generally uses words such as &#147;believe,&#148; &#147;may,&#148; &#147;could,&#148; &#147;will,&#148; &#147;intend,&#148; &#147;expect,&#148;
&#147;anticipate,&#148; &#147;plan,&#148; and similar expressions to identify forward-looking statements. One should
not place undue reliance on these</I>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>forward-looking statements. The Company&#146;s actual results could differ materially from those
anticipated in the forward-looking statements for many unforeseen factors. See Champions
Biotechnology&#146;s </I><I>Form 10-K</I><I> for the fiscal year ended April&nbsp;30, 2010 for a discussion of such risks,
uncertainties and other factors. Although the Company believes the expectations reflected in the
forward-looking statements are reasonable, they relate only to events as of the date on which the
statements are made, and Champions Biotechnology&#146;s future results, levels of activity, performance
or achievements may not meet these expectations. The Company does not intend to update any of the
forward-looking statements after the date of this press release to conform these statements to
actual results or to changes in Champions Biotechnology&#146;s expectations, except as required by law.</I>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>CHAMPIONS BIOTECHNOLOGY, INC. WEB SITE: www.championsbiotechnology.com</B>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
